Annovis Bio, Inc. (ANVS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
21/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseANVS / S&P -16.59% / 15.20% |
LoseANVS / S&P ANVS unavailable / 15.00% |
LoseANVS / S&P -11.82% / 50.40% |
| 2026-Q10/3 |
LoseANVS / S&P -35.55% / -4.33% |
LoseANVS / S&P ANVS unavailable / 11.30% |
LoseANVS / S&P -20.47% / 27.70% |
| 2025-Q41/3 |
WinANVS / S&P 67.15% / 2.65% |
LoseANVS / S&P ANVS unavailable / 9.00% |
LoseANVS / S&P -45.10% / 13.40% |
| 2025-Q30/3 |
LoseANVS / S&P -4.61% / 8.12% |
LoseANVS / S&P ANVS unavailable / 4.61% |
LoseANVS / S&P -67.94% / 13.45% |
| 2025-Q21/3 |
WinANVS / S&P 44.67% / 10.94% |
LoseANVS / S&P ANVS unavailable / 4.83% |
LoseANVS / S&P -60.35% / 10.63% |
| 2025-Q10/3 |
LoseANVS / S&P -70.18% / -4.27% |
LoseANVS / S&P ANVS unavailable / 4.98% |
LoseANVS / S&P -62.61% / 10.57% |
| 2024-Q40/3 |
LoseANVS / S&P -37.59% / 2.41% |
LoseANVS / S&P ANVS unavailable / 5.25% |
LoseANVS / S&P -58.20% / 6.15% |
| 2024-Q31/3 |
WinANVS / S&P 39.93% / 5.89% |
LoseANVS / S&P ANVS unavailable / 5.89% |
LoseANVS / S&P -5.31% / 6.11% |
| 2024-Q21/3 |
LoseANVS / S&P -51.60% / 4.28% |
LoseANVS / S&P ANVS unavailable / 5.38% |
WinANVS / S&P 32.30% / 5.12% |
| 2024-Q11/3 |
LoseANVS / S&P -36.36% / 10.56% |
LoseANVS / S&P ANVS unavailable / 5.71% |
WinANVS / S&P 62.89% / 5.59% |
| 2023-Q42/3 |
WinANVS / S&P 97.05% / 11.69% |
LoseANVS / S&P ANVS unavailable / 6.81% |
WinANVS / S&P 96.77% / 7.78% |
| 2023-Q31/3 |
LoseANVS / S&P -33.59% / -3.27% |
LoseANVS / S&P ANVS unavailable / 7.52% |
WinANVS / S&P 61.86% / -5.03% |
| 2023-Q21/3 |
LoseANVS / S&P -7.27% / 8.74% |
LoseANVS / S&P ANVS unavailable / 9.50% |
WinANVS / S&P 56.68% / -8.57% |
| 2023-Q12/3 |
WinANVS / S&P 14.74% / 7.50% |
LoseANVS / S&P ANVS unavailable / 10.77% |
WinANVS / S&P 69.71% / -15.69% |
| 2022-Q41/3 |
LoseANVS / S&P -1.97% / 7.56% |
LoseANVS / S&P ANVS unavailable / 11.88% |
WinANVS / S&P 63.16% / -17.99% |
| 2022-Q32/3 |
WinANVS / S&P 20.81% / -4.88% |
LoseANVS / S&P ANVS unavailable / 13.47% |
WinANVS / S&P 106.38% / -1.41% |
| 2022-Q22/3 |
WinANVS / S&P -15.06% / -16.10% |
LoseANVS / S&P ANVS unavailable / 13.71% |
WinANVS / S&P 104.13% / 11.04% |
| 2022-Q10/3 |
LoseANVS / S&P -24.06% / -4.60% |
LoseANVS / S&P ANVS unavailable / 15.97% |
LoseANVS / S&P ANVS unavailable / 42.23% |
| 2021-Q40/3 |
LoseANVS / S&P -44.63% / 11.03% |
LoseANVS / S&P ANVS unavailable / 15.00% |
LoseANVS / S&P ANVS unavailable / 96.40% |
| 2021-Q30/3 |
LoseANVS / S&P -62.90% / 0.58% |
LoseANVS / S&P ANVS unavailable / 10.77% |
LoseANVS / S&P ANVS unavailable / 69.42% |
| 2021-Q21/3 |
WinANVS / S&P 206.74% / 8.55% |
LoseANVS / S&P ANVS unavailable / 6.58% |
LoseANVS / S&P ANVS unavailable / 51.81% |
| 2021-Q11/3 |
WinANVS / S&P 270.03% / 6.17% |
LoseANVS / S&P ANVS unavailable / -1.06% |
LoseANVS / S&P ANVS unavailable / 7.39% |
| 2020-Q41/3 |
WinANVS / S&P 56.76% / 12.15% |
LoseANVS / S&P ANVS unavailable / -3.72% |
LoseANVS / S&P ANVS unavailable / -33.42% |
| 2020-Q31/3 |
WinANVS / S&P 10.57% / 8.93% |
LoseANVS / S&P ANVS unavailable / -2.04% |
LoseANVS / S&P ANVS unavailable / -27.10% |
| 2020-Q21/3 |
WinANVS / S&P 45.00% / 20.54% |
LoseANVS / S&P ANVS unavailable / -0.46% |
LoseANVS / S&P ANVS unavailable / -27.11% |
| 2020-Q10/3 |
LoseANVS / S&P ANVS unavailable / -19.60% |
LoseANVS / S&P ANVS unavailable / 3.47% |
LoseANVS / S&P ANVS unavailable / -14.75% |
| 2019-Q40/3 |
LoseANVS / S&P ANVS unavailable / 9.07% |
LoseANVS / S&P ANVS unavailable / 5.36% |
LoseANVS / S&P ANVS unavailable / 2.99% |
| 2019-Q30/3 |
LoseANVS / S&P ANVS unavailable / 1.70% |
LoseANVS / S&P ANVS unavailable / 5.02% |
LoseANVS / S&P ANVS unavailable / 0.21% |
| 2019-Q20/3 |
LoseANVS / S&P ANVS unavailable / 4.30% |
LoseANVS / S&P ANVS unavailable / 6.64% |
LoseANVS / S&P ANVS unavailable / 8.65% |
| 2019-Q10/3 |
LoseANVS / S&P ANVS unavailable / 13.65% |
LoseANVS / S&P ANVS unavailable / 8.12% |
LoseANVS / S&P ANVS unavailable / 14.29% |
| 2018-Q40/3 |
LoseANVS / S&P ANVS unavailable / -13.52% |
LoseANVS / S&P ANVS unavailable / 9.05% |
LoseANVS / S&P ANVS unavailable / 18.23% |
| 2018-Q30/3 |
LoseANVS / S&P ANVS unavailable / 7.71% |
LoseANVS / S&P ANVS unavailable / 10.21% |
LoseANVS / S&P ANVS unavailable / 19.06% |
| 2018-Q20/3 |
LoseANVS / S&P ANVS unavailable / 3.43% |
LoseANVS / S&P ANVS unavailable / 9.03% |
LoseANVS / S&P ANVS unavailable / 14.46% |
| 2018-Q10/3 |
LoseANVS / S&P ANVS unavailable / -0.76% |
LoseANVS / S&P ANVS unavailable / 7.68% |
LoseANVS / S&P ANVS unavailable / 12.46% |
| 2017-Q40/3 |
LoseANVS / S&P ANVS unavailable / 6.64% |
LoseANVS / S&P ANVS unavailable / 7.03% |
LoseANVS / S&P ANVS unavailable / 13.82% |
| 2017-Q30/3 |
LoseANVS / S&P ANVS unavailable / 4.48% |
LoseANVS / S&P ANVS unavailable / 5.68% |
LoseANVS / S&P ANVS unavailable / 17.57% |
| 2017-Q20/3 |
LoseANVS / S&P ANVS unavailable / 3.09% |
LoseANVS / S&P ANVS unavailable / 4.83% |
LoseANVS / S&P ANVS unavailable / 17.74% |
| 2017-Q10/3 |
LoseANVS / S&P ANVS unavailable / 6.07% |
LoseANVS / S&P ANVS unavailable / 3.67% |
LoseANVS / S&P ANVS unavailable / 13.32% |
| 2016-Q40/3 |
LoseANVS / S&P ANVS unavailable / 3.82% |
LoseANVS / S&P ANVS unavailable / 2.09% |
LoseANVS / S&P ANVS unavailable / 7.05% |
| 2016-Q30/3 |
LoseANVS / S&P ANVS unavailable / 3.85% |
LoseANVS / S&P ANVS unavailable / 0.20% |
LoseANVS / S&P ANVS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ANVS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -21.65% | 20.78% |
| Annualized return | -21.65% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ANVS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -95.12% | 83.14% |
| Annualized return | -45.35% | 12.86% |
10Y · 2020-01-29 to 2026-08-27
| Metric | ANVS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -81.13% | 319.30% |
| Annualized return | -15.36% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |